UT Southwestern Medical Center researchers have identified an Achilles heel in a metabolic pathway crucial to stopping the growth of lung cancer cells.
At the heart of this pathway lies PPARã (peroxisome proliferation-activated receptor gamma), a protein that regulates glucose and lipid metabolism in normal cells. Researchers demonstrated that by activating PPARã with antidiabetic drugs in lung cancer cells, they could stop these tumor cells from dividing.
Advertisement"We found that activation of PPARã causes a major metabolic change in cancer cells that impairs their ability to handle oxidative stress," said Dr. Ralf Kittler, Assistant Professor in the Eugene McDermott Center for Human Growth and Development, the Department of Pharmacology, the Harold C. Simmons Cancer Center and the Cecil H. and Ida Green Center for Reproductive Biology Sciences at UT Southwestern.
"The increased oxidative stress ultimately inhibits the growth of the tumor. We found that activation of PPARã killed both cancer cells grown in a dish and tumors in mice, in which we observed near complete tumor growth inhibition," said Dr. Kittler, the John L. Roach Scholar in Biomedical Research of UT Southwestern's Endowed Scholars Program.
The study, published in the journal Cell Metabolism, builds on a large body of work showing that metabolism in cancer cells is altered when compared to normal cells. Changes in metabolism can make cancer cells more vulnerable to therapeutic agents, which make them a good target to investigate for cancer therapy. The new research also extends earlier observations made by Dr. Steven Kliewer, Professor of Molecular Biology and Pharmacology, who first identified that thiazolidinediones target PPARã. Dr. Kliewer holds the Nancy B. and Jake L. Hamon Distinguished Chair in Basic Cancer Research.
Dr. Kittler and his team determined that PPARã activation triggers changes in glucose and lipid metabolism that cause an increase in the levels of reactive oxygen species (ROS). ROS are highly reactive oxygen-containing molecules that damage cells when present at high levels, a phenomenon known as oxidative stress. It is this increase in ROS that eventually stops the cancer cells from dividing.
"The abnormal metabolism in cancer cells frequently causes increased oxidative stress, and any further increase can 'push' cancer cells over the cliff," said Dr. Kittler, UT Southwestern's first Cancer Prevention and Research Institute of Texas (CPRIT) Scholar in Cancer Research.
The findings suggest that targeting PPARã could be a promising new therapeutic approach for lung cancer and potentially other cancers. The researchers saw that activating PPARã caused similar molecular changes in breast cancer cells.
"This is an important finding because the drugs that activate PPARã include FDA-approved antidiabetic drugs that are relatively well tolerated compared to chemotherapy. Knowing their mechanism of action provides us with clues for selecting tumors that may be responsive to this treatment, for combining these drugs with anti-cancer drugs to make therapy more effective, and for developing markers to measure the response of tumors to these drugs in patients," said Dr. Kittler, Director of the McDermott Next-Generation Sequencing Core at UT Southwestern.
"Of course, further study will be required to determine the therapeutic effectiveness of PPARã-activating drugs for lung cancer treatment," he added.